Thrombocytopenic purpura - eltrombopag (TA293)
Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
This guidance updates and replaces NICE technology appraisal 205 (published in October 2010)
What has NICE said?
NICE recommends eltrombopag as a possible treatment for some adults with chronic immune (idiopathic) thrombocytopenic purpura (which is sometimes shortened to chronic ITP).
Who can have eltrombopag?
You should be able to have eltrombopag if you have had your spleen removed, or if you have not had your spleen removed because you can’t have the operation, only if:
- your chronic ITP has not improved even though you have tried other available treatments, or
- you have severe chronic ITP and a high risk of bleeding that needs frequent courses of emergency treatment.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.
NICE recommended eltrombopag because it is effective and costs less than other treatments available on the NHS.
This page was last updated: 17 March 2014
- Web format
- Full Guidance (PDF)
- Eltrombopag ar gyfer pwrpwra thrombosytopenig imiwnedd cronig (idiopathig): Gwybodaeth i'r cyhoedd (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.